The first vaccines will arrive in spring, but this will not be the end of the pandemic, says the director of the European Medicines Agency – Coronavirus.



[ad_1]

The first vaccines against Covid-19 will arrive in the EU next spring, “if all goes well,” Guido Rasi, executive director of the European Medicines Agency (EMA), said on Friday, according to Reuters and EFE, quoted by Agerpres.

“It is very difficult, almost impossible to have the vaccine by 2020. If all goes well, in the first months of 2021 we could have three vaccines approved by the EMA,” said the director of this agency in a statement to Skytg24.

“I think that, if we are lucky, many of those who want to be vaccinated will be able to do so in the summer of 2021”, after the doses planned for spring, vaccination for risk categories will begin.

However, Guido Rasi warned that “the arrival of the vaccine will be the beginning of the end of the pandemic, not the end” and “only after a year since the vaccine will be available will we see the pandemic significantly reduced.”

Currently, the EMA is evaluating experimental vaccines developed by Pfizer, AstraZeneca and Moderna to accelerate their authorization if clinical trials demonstrate their efficacy and safety.

However, the head of the European Agency pointed out that, regardless of the conclusions of these tests and analyzes, the response of people to the vaccine and the duration of the immunity acquired after administration should be evaluated in practice over a period of at least least six months of the vaccination campaign. that. He also added that the mask and social distancing will continue to be necessary even after the vaccination of the population begins.

As for treatments and medications for Covid-19, according to the director of the EMA, “there are at least two or three medications or treatment regimens that are certainly effective, such as taking cortisone at the right time, not too early and not too much. late, or anticoagulants. “

He also points out that “the possibility of starting to use monoclonal antibodies is now very accessible”, the treatment benefited by the president of the United States, Donald Trump.

[ad_2]